PropThink: Vertex Drops One Drug, Advances Another as HCV Segment Heats Up

PropThink: Vertex Drops One Drug, Advances Another as HCV Segment Heats Up

[ACN Newswire] – By Jake KingOn Tuesday, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that while it would be advancing its developmental Hepatitis C (HCV) treatment, ALS-2200, into Phase II testing, ALS-2158 didn’t make … more

View todays social media effects on IDIX

View the latest stocks trending across Twitter. Click to view dashboard

Share this post